Volume 26, Number 9—September 2020
CME ACTIVITY - Synopsis
Invasive Infections with Nannizziopsis obscura Species Complex in 9 Patients from West Africa, France, 2004–20201
On This Page
Article Metrics
Dea Garcia-Hermoso
, Samia Hamane, Arnaud Fekkar, Arnaud Jabet, Blandine Denis, Martin Siguier, Guy Galeazzi, Elie Haddad, Sophie Brun, Valérie Vidal, Gilles Nevez, Rozenn Le Berre, Maud Gits-Muselli, Fanny Lanternier, and Stéphane Bretagne
, Samia Hamane, Arnaud Fekkar, Arnaud Jabet, Blandine Denis, Martin Siguier, Guy Galeazzi, Elie Haddad, Sophie Brun, Valérie Vidal, Gilles Nevez, Rozenn Le Berre, Maud Gits-Muselli, Fanny Lanternier, and Stéphane BretagneIntroduction
Medscape CME ACTIVITY
In support of improving patient care, this activity has been planned and implemented by Medscape, LLC and Emerging Infectious Diseases. Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Medscape, LLC designates this Journal-based CME activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
All other clinicians completing this activity will be issued a certificate of participation. To participate in this journal CME activity: (1) review the learning objectives and author disclosures; (2) study the education content; (3) take the post-test with a 75% minimum passing score and complete the evaluation at ; and (4) view/print certificate.
Release date: August 14, 2020; Expiration date: August 14, 2021
Learning Objectives
Upon completion of this activity, participants will be able to:
• Assess the clinical features of invasive fungal infection with N. obscura species complex, based on a series of 9 new confirmed human cases from 2004 to 2020
• Evaluate the microbiological features of invasive fungal infection with N. obscura species complex, based on a series of 9 new confirmed human cases from 2004 to 2020
• Determine the clinical implications of features of invasive fungal infection with N. obscura species complex, based on a series of 9 new confirmed human cases from 2004 to 2020
CME Editor
Jude Rutledge, BA, Technical Writer/Editor, Emerging Infectious Diseases. Disclosure: Jude Rutledge has disclosed no relevant financial relationships.
CME Author
Laurie Barclay, MD, freelance writer and reviewer, Medscape, LLC. Disclosure: Laurie Barclay, MD, has disclosed no relevant financial relationships.
Authors
Disclosures: Dea Garcia-Hermoso, PhD; Samia Hamane, MD; Arnaud Jabet, MS; Blandine Denis, MD, PhD; Guy Galeazzi, MD; Elie Haddad, MD; Sophie Brun, MD, PhD; Valérie Vidal, MD; Gilles Nevez, MD, PhD; Rozenn Le Berre, MD, PhD; Maud Gits-Muselli, MD; Fanny Lanternier, MD, PhD; and Stéphane Bretagne, MD, PhD, have disclosed no relevant financial relationships. Arnaud Fekkar, PharmD, PhD, has disclosed the following relevant financial relationships: served as a speaker or a member of a speakers bureau for Gilead; received grants for clinical research from Janssen. Martin Siguier, MD, has disclosed the following relevant financial relationships: served as an advisor or consultant for Viiv Healthcare; other (travel expenses reimbursement) from Gilead.
Abstract
Nine new human invasive infections caused by the keratinophilic fungi Nannizziopsis obscura have been reported in France since 2004. The patients had variable clinical manifestations, had frequent dissemination, were mainly T-cell immunocompromised, and all originated from sub-Saharan West Africa. Before collection of the isolates, the etiologies of these infections were often misidentified, underscoring the extent of microscopic and cultural polymorphisms. All isolates but 1 had low MICs for the 8 antifungal drugs tested. When treated, patients received mainly azole therapy. Two of 7 patients with a known outcome died. We performed multilocus sequence analysis of N. obscura clinical strains and several strains of Nannizziopsis spp. isolated from reptiles. The human strains were clearly differentiated from the animal strains. N. obscura might be endemic to West Africa and responsible for undetected infections, which might become reactivated when immunosuppression occurs. N. obscura infection is probably underestimated because only sequencing enables proper identification.
Nannizziopsis spp. are described as keratinophilic ascomycetous fungi that cause dermal infections with frequently fatal outcomes in various reptiles (e.g., lizards, geckos, chameleons, iguanas, snakes, and crocodiles), mainly in captivity (1,2). Nannizziopsis spp. belong to the order of Onygenales and the recently described family of Nannizziopsidaceae (1). In humans, invasive Nannizziopsis spp. infection seems rare; only 5 cases have been reported to date (1,3–7). Such an observation suggests an actual rarity, a recent emergence because of modification in the ecoepidemiology (e.g., new populations at risk [8]), or previous underdiagnoses or misdiagnoses because of a lack of definite identification.
We describe 9 human cases of invasive fungal infection with N. obscura species complex identified in France during 2004–2020 (Table 1), along with the initial identification from the 5 reporting hospitals. Isolates were sent to France’s National Reference Center for Invasive Mycoses and Antifungals, where a polyphasic identification combining phenotypic features and molecular data was performed. Seven of the 9 cases were diagnosed after 2016.
Patient 1 was 49-year-old HIV-positive man from Mali who was hospitalized for a liver abscess discovered in August 2004 during a stay in Mali. He was afebrile but had advanced AIDS (zero CD4 cell/mm3). A liver needle aspiration showed hyphae with arthroconidia. The first identified colonies were Trichosporon spp., based on a positive urease test and presence of arthroconidia. The patient was given liposomal amphotericin B and metronidazole. After 15 days, the patient returned to Mali for personal reasons; no follow-up was possible. At that time, the organism had been identified as Chrysosporium spp.
Patient 2 was a 50-year-old man who came from Mali to undergo heart transplantation in January 2009 after 9 months of hospitalization for cardiac insufficiency. After transplantation, the patient had cytomegalovirus reactivation and multivisceral failure. One month later, he had onset of bacterial mediastinitis. He was surgically treated and received wide-spectrum antibiotics but no antifungals. The immunosuppressive therapy consisted of prednisone (15 mg/d) and ciclosporine. A serum sample was negative for Aspergillus galactomannan. Two months later (just 2 days before the death of the patient), a blood culture was positive, and the isolate was identified as Geotrichum spp. or Chrysosporium spp.
Patient 3 was a 58-year-old woman with diabetes who was from Mali but had been living in France for 30 years. In 2017, she reported a 2-week history of asthenia and chest pain without fever. She had renal transplantation in 2016 and was receiving tacrolimus, mycophenolate, and prednisone (5 mg/d). A computed tomography (CT) scan revealed an irregular lung nodule (14 mm in diameter). She received amoxicillin/clavulanic acid. Three months later, she had an abscess of the left thigh and multiple nodular skin lesions on both legs. A new CT scan showed an enlargement of the pulmonary nodule. Direct examination of the skin and lung biopsies revealed septate and vesiculous hyphae, and the culture resembled Trichophyton spp., which was eventually confirmed as N. obscura upon sequencing. Serum β-D-glucan was strongly positive (>500 pg/mL, positivity threshold >80 pg/ml), and serum Aspergillus galactomannan antigen was repeatedly negative. A whole-body positron emission tomography (PET)–CT scan showed multiple clinically latent hypermetabolic lesions (in the nasal septum, left breast, and mediastinal nodes). Voriconazole was initiated, then switched to posaconazole after N. obscura identification. The dose of tacrolimus was reduced, and mycophenolate mofetil was replaced by azathioprine. At 6 months, a new PET-CT scan showed a residual hypermetabolic pulmonary lesion. Posaconazole was stopped after 8 months. No relapse had occurred as of 1 year later.
Figure 1. Features of Nannizziopsis obscura infections in patients from West Africa, France 2004–2020. A) Ulcerative lesions. B) Septate hyphae and arthroconidia on a calcofluor white direct examination (original magnification ×200). C) Macroscopic...
Patient 4 was a 62-year-old man from Guinea who had been living in France for 12 years (recent trip to Guinea occurred »1 year before). He was hospitalized in July 2017 for several suppurated lesions on the right fibula (Figure 1, panel A) that were unresponsive to amoxicillin/clavulanic acid treatment. He had undergone renal transplantation in 2009 for hypertensive nephropathy and received mycophenolate mofetil, tacrolimus, and prednisone (5 mg/d). A CT scan confirmed tissue infiltration with small abscesses but showed no sign of bone involvement. Large-scale debridement was performed, and direct examination of infected tissues showed regular septate hyphae and arthroconidia (Figure 1, panel B). Yeast-like fungi appeared on Sabouraud–chloramphenicol–gentamycin slants. Microscopic examination showed arthroconidia, and the urease test was positive, suggesting the presence of Trichosporon spp. A whole-body PET-CT scan revealed asymptomatic hypermetabolic lesions in the contralateral leg and lung micronodules. Voriconazole was started when trichosporonosis was suspected and switched to posaconazole with the identification of N. obscura. Serum β-D-glucan was strongly positive (>500 pg/mL), whereas Aspergillus galactomannan antigen detection was negative. At 6 months, a PET-CT scan showed residual hypermetabolism around the right ankle. Onychomycosis of the right toe was noted, and a specimen was taken. Direct examination showed hyphae, but the culture was negative. Posaconazole was maintained for 2 years, with tacrolimus and prednisone (5 mg/d). A new PET-CT scan showed no hypermetabolic lesion.
Patient 5 was a 69-year-old woman from Guinea-Bissau who had been living in France for 10 years (her most recent trip to Guinea-Bissau occurred in 2016). She was admitted for the investigation of lung lesions. She had been treated for advanced mantle cell lymphoma in 2017, resulting in complete remission. In June 2018, a thoracic CT scan showed lymphadenopathy, lung nodules, and condensations treated with intravenous antibiotics and rituximab. In September 2018, disseminated nodular hyperchromic skin lesions appeared, and skin biopsies showed large septate hyphae with arthroconidia. A combination of voriconazole and liposomal amphotericin B was started for probable invasive mold infection. White mold colonies were observed after 5 days culture, and a presumptive identification of Trichophyton spp. was made. Terbinafine was added and but was exchanged for voriconazole and liposomal amphotericin B when N. obscura was identified. Thirty days after admission, magnetic resonance imaging of the central nervous system showed diffuse, embolic-looking ischemia. Viral PCRs were negative in cerebrospinal fluid. Serum β-D-glucan was strongly positive (>500 pg/mL), and serum galactomannan was negative. Liver biopsy confirmed adult T-cell lymphoma or leukemia associated with human T-cell lymphotropic virus type 1 positivity. The patient died 3 weeks after admission despite intensive care and antifungal treatment.
Patient 6 was a 27-year-old woman from Guinea who was breast-feeding. She had been living in France since September 2017 and was seen at a tuberculosis control center in October 2018. A chest radiograph showed a mediastinal mass, which was confirmed by a chest CT scan. The mass (7 × 5 × 5 cm) invaded the left upper lobe, and thickening of the anterior arch of the second left rib was observed. She had no notable medical history. Pathologic examination of the surgically resected mediastinal mass showed hyphae inside an inflammatory and fibrous reaction invading the thymus, the brachiocephalic veins, the left upper lobe, and the chest wall. Serum β-D-glucan was positive (306 pg/mL). A first presumptive identification on culture was of Trichophyton spp. Posaconazole was started, then switched with voriconazole when N. obscura was identified. A reduction in mass size (from 71 × 39 mm to 62 × 36 mm) was observed on a CT scan after 7 months of treatment. The investigations of Card9 and Stat1 mutations, 2 genes known to be responsible for higher susceptibility to invasive fungal infections (9), showed wild type genotypes. Follow-up after that point was not possible.
Patient 7 was a 38-year-old man from Mali who was hospitalized for visual disturbance, retroorbital pain, and vomiting in September 2018. He had been living in France since 1990, making regular visits to relatives in Mali. He had undergone a renal transplant in 2015 and was receiving mycophenolate mofetil, tacrolimus, and prednisone (5 mg/d). He had experienced an acute rejection in March 2018, which was treated by high-dose methylprednisone. A brain CT scan showed hypodense lesions with mass effect. Results of magnetic resonance imaging without injection supported the diagnosis of glioblastoma. A cerebral biopsy showed numerous branched hyphae. Candida spp. infection was suspected, and liposomal amphotericin B (5 mg/d) was started in combination with fluconazole IV (200 mg/d). The treatment resulted in an improvement of the visual disturbance, and a new magnetic resonance imaging result confirmed the reduction of the mass effect. Culture results were positive, and the final identification made was Nannizziopsis spp. Serum β-D-glucan was strongly positive (>500 pg/mL), and serum galactomannan was negative. On October 9, fluconazole was switched for voriconazole, and the liposomal amphotericin B was maintained. Meanwhile, the patient experienced a chronic rejection of the graft, and hemodialysis was restarted on November 23. He was alive as of 12 months later.
Patient 8 was a 79-year-old man from Mali who had been living in France since 1963 (his most recent trip to Mali occurred in 2016). In August 2019, he sought care for an ulcerative lesion of the fifth right finger that had been evolving for several months. He had undergone a renal transplant in 2014 and was receiving mycophenolate mofetil, tacrolimus, and prednisone (5 mg/d). A pulmonary nodule was observed in 2017 and was only surveyed. Because of a recent increase in size (from 9 to 13 cm in diameter), a PET-CT scan was performed in April 2019 and showed multiple hypermetabolic pulmonary, abdominal, and muscular (left thigh) nodules. The pulmonary nodule was surgically removed in June 2019, and a necrotic abscess with hyphae was observed by the pathologist (no culture was performed). The evolution was indolent, although the patient had lost 10 kg in 6 months. In August 2019, a skin biopsy showed hyphae, and the culture was identified as N. obscura upon sequencing. Serum β-D-glucan was positive (255 pg/mL), and serum galactomannan was negative. Itraconazole was started in August 2019. The patient had been seen in July 2018 because of the same ulcerative lesion of his right hand. A swab specimen yielded a mold colony identified as Trichophyton rubrum, which was considered not clinically relevant. The identification of the stored isolate yielded N. obscura, which confirmed that the infection had been ongoing for >1 year. The patient was well as of 4 months after starting azole therapy.
Patient 9 was a 65-year-old man from Mali who had been living in France for >20 years. In December 2019, he sought care for a mass in front of the left clavicle that had appeared 6 months earlier during a stay in Bamako, Mali. The patient had undergone a renal transplant in 2018 and was receiving cyclosporine, tacrolimus, and prednisone (5 mg/d). A CT scan showed bone lysis of the clavicle with a subcutaneous abscess. A biopsy was performed, and the pathologist reported inflammation with hyphae. Spontaneous fistula occurred, yielding pus. Nannizziopsis sp. was identified in the culture. A PET-CT showed hypermetabolism of the left clavicle, and the presternal region extended to the manubrium along with hypermetabolism of a pulmonary nodule of the lingula. Serum β-D-glucan results were positive (>520 pg/mL). Treatment with voriconazole was started and a reappraisal scheduled after 12 weeks.
Morphologic Identification and Antifungal-Susceptibility Testing
Ten clinical isolates (2 isolates for patient 8) were checked for purity and subsequently subcultured on potato dextrose agar (PDA) (BD Diagnostic Systems, ; ttps://www.fishersci.fr/) and malt extract agar (MEA) 2% (Oxoid, ) for 15 days at 30°C, 37°C, and 40°C to study fungal growth and sporulation. The type strain of N. obscura (isolate no. UAMH5875) was analyzed in parallel. Microscopic characteristics were examined on 5- to 7-day-old MEA slide cultures incubated at 30°C. Antifungal-susceptibility profiles were screened according to a slightly modified European Committee on Antimicrobial Susceptibility Testing procedure (10). All antifungal drugs were purchased from Alsachim ().
Molecular Characterization and Phylogenetic Analysis
We performed DNA extraction and amplified fragments of the internal transcribed region (ITS), the D1–D2 region of the large subunit (LSU) ribosomal DNA, and the actin gene (11) (Appendix). We conducted a preliminary similarity searching using BLASTn () against curated fungal reference databases. We conducted multiple sequence alignments and single-gene phylogenies in MEGA7 (12). In addition to the clinical isolates and the type strain of N. obscura, we incorporated the corresponding sequences of N. draconii, N. chlamydospora, N. guarroi, N. vriesii, and N. arthrosporioides that are published in GenBank (Appendix). N. hominis was not included because of the lack of LSU and actin sequences in the public databases. Phylogenetic analysis was done with a neighbor-joining method by using MEGA7 and with the maximum-likelihood method by using PhyML 3.0 (13) subjected to smart model selection at the NGPhylogeny integrative web service () (14).
Ethics Considerations
We obtained approval from the Commission Nationale de l’Informatique et des Libertés, the national data-protection agency in France (approval no. 903395). This step ensured that the patients’ data were kept anonymous according to national regulations.
Morphology
All clinical strains and the type strain grew well on PDA at 30°C and 37°C. No growth was observed at 40°C. Cultures on PDA and MEA at 30°C were white with low aerial mycelium and a velvety to powdery texture, rarely zonate, or heaped and with a yellowish coloring on the reverse (Figure 1, panel C). In general, microscopic observations showed the typical, although nonspecific, features of the genus Nannizziopsis (e.g., hyaline, septate, smooth-walled hyphae). All isolates produced sessile conidia and arthroconidia, and some produced short hyphal branches in a wavelike motion (undulate hyphae) (Figure 1, panels D–F) (5).
Antifungal Susceptibility Testing
The MICs or minimal effective concentrations (MECs) of all 8 antifungals were low except for 1 strain. Median MICs were 0.25 mg/L (range 0.06–1 mg/L) for amphotericin B, 0.125 mg/L (range 0.014–4 mg/L) for itraconazole, 0.06 mg/L (range 0.03–2 mg/L) for voriconazole, 0.06 mg/L (range 0.014–2 mg/L) for posaconazole, 0.125 mg/L (range 0.06–2 mg/L) for isavuconazole, and 0.06 mg/L (range 0.014–0.5 mg/L) for terbinafine. Median MEC was 0.5 mg/L (range 0.25–1 mg/L) for caspofungin and 0.015 mg/L (range 0.015–0.06 mg/L) for micafungin.
Molecular Characterization and Phylogenetic Analyses
Similarity comparisons in public databases showed that all isolates belong to the genus Nannizziopsis and had percentage identity ranges of 96.0%–99.8% (475 bp length) for LSU, 88.0%–99.0% (>700 bp length) for ITS, and 85.0%–98.7% (>500 bp length) for actin genes. N. guarroi (GenBank accession no. MH874904) had the highest number of hits for LSU, whereas N. vriesii (accession no. HF547893) had the highest number of hits for the actin gene. For ITS, the highest-scoring hits corresponded to a Nannizziopsiaceae strain (GenBank accession no. MF688808; 99%), followed by Nannizziopsis spp. (GenBank accession no. KY771169; 98.7%).
Multiple alignments for ITS2, LSU, and actin regions consisted of 283, 476, and 572 positions, of which 33 (11.6%), 31 (6.5%), and 128 (22.4%) were variable, respectively. The topologies observed on individual gene trees were very similar to those observed on a combined tree. The combined LSU-actin-ITS2 dataset of 1,331 positions had 192 (14.4%) of variable nucleotides.
Figure 2. Maximum-likelihood tree obtained from combined large subunit ribosomal DNA, actin, and internal transcribed spacer 2 sequence data obtained from genomic analysis of Nannizziopsis obscura isolates from 9 patients from West Africa,...
The multilocus phylogenetic analysis revealed 2 main well-supported clades: 1 grouping all the clinical isolates, including the type strain of N. obscura and the named N. obscura species complex clade, and an additional clade assembling the 3 reptile Nannizziopsis species isolated from Iguana iguana (N. guarroi) and from bearded dragons, Pogona vitticeps (N. draconii, N. chlamydospora). N. vriesii and N. arthrosporioides were separated from the rest of the isolates and from each another (Figure 2).
We describe 9 new cases of proven invasive infection with the N. obscura species complex in France. The most frequent clinical localizations were subcutaneous tissues (6 patients) and lung nodules (6 patients) (Table 1). Eight of the 9 patients had T-cell immunosuppression associated mainly with the prevention of solid organ rejection. The constant feature was the sub-Saharan origin of all patients. The infecting agent was initially misidentified as Geotrichum spp., Trichosporon spp., and Trichophyton spp. in the 5 different participating hospitals (Table 1). Confusion of Nannizziopsis spp. with Geotrichum spp. (3,5), Trichosporon spp., or Trichophyton spp (5) are also common in the literature (Table 2). The most common finding upon direct examination at the microbiologic laboratories was the presence of nonspecific hyphae. On culture, Nannizziopsis spp. do not exhibit specific features (yeast-like or woolly aspect). Some characteristics of Nannizziopsis spp. are even shared with dermatophytes (e.g., cycloheximide tolerance and aleurioconidia). Dermatophytes can be involved in aggressive skin diseases, especially after renal transplantation (15). Moreover, empiric azole treatment might control the infection without a definite diagnosis. Because multilocus sequencing of the pathogen is often restricted to unusual localizations or therapeutic failures, a clear knowledge of the spectrum of Nannizziopsis spp. infections is lacking, which can explain, at least in part, the rarity of the cases reported.
The initial diagnosis also can be confused by the considerable diversity of the clinical manifestations. Some infections appeared as subacute; others were relatively indolent during periods of months or years. Records for these 9 patients and from the show that the underlying diseases are also diverse, although dominated by HIV infection before 2006 (3 patients) and solid organ transplantation (8 patients) after 2006; the most frequent clinical localizations were subcutaneous tissues (8 patients) and lung (7 patients) (Tables 1, 2). For some patients, the infection manifested as disseminated disease with brain abscess, lung nodules, or positive blood culture (Tables 1, 2). The association of serum β-D-glucan positivity and galactomannan negativity (7 and 6 patients tested in the 9-patient series, respectively) seems a useful adjunct, albeit unspecific. As a consequence, the suspicion of Nannizziopsis spp. infection cannot rely on a specific clinical manifestation and requires a tissue biopsy.
Our molecular study places all 10 N. obscura isolates (including 2 recovered from patient 8) into a well-supported phylogenetic lineage, separate from reptile isolates (Figure 2). Recent taxonomic revisions for the former Chrysosporium anamorph of N. vriesii complex resulted in the assignment of several species within the genus Nannizziopsis or within the 2 new genera of Paranannizziopsis and Ophiodiomyces (1,5). So far, only 2 species (N. obscura and N. hominis) have been definitely implicated in human pathology (3,5). The species N. infrequens was determined not to be responsible for an invasive infection and was disregarded by clinicians (16). Thus, N. hominis was reported in 3 patients before 2000, and N. obscura was reported in 4 patients after 2005 (5) and in 9 cases since then. N. infrequens and N. hominis exhibit good growth at 35°C, in contrast to the Nannizziopsis species implicated in reptile infections (5). Although our study clearly differentiates the human N. obscura isolates from our case series from the reptile isolates, the modest branch support value for the N. obscura clade (0.71 by maximum-likelihood method) suggests the possibility of potential new species. More taxa and additional gene sequences should be studied to investigate this hypothesis.
The issue of the portal of entry remains unclear. Subcutaneous nodules, ulcerative skin lesions, or both are frequently noted (e.g., in patients 2, 3, 4, 5, 8, and 9) (Table 1) and could have been the initial site of infection. Skin can be suspected because Nannizziopsis species are keratinophilic and cause extensive dermatitis with erosions and subsequent invasion of the subcutaneous structures in reptiles (1,2). When specifically investigated in this case series (i.e., patients 3 and 4) (Table 1), no Nannizziopsis organisms were recovered from skin or nail samples, even when patients had dermatomycoses or onyxis. On the other hand, the frequency of dissemination suggests inhalation as a possible route, with subcutaneous nodules as tissue localizations other than lung as a consequence of blood dissemination. Therefore, the infection scenario described for reptiles might not apply to humans.
We cannot provide firm recommendations for antifungal treatment because of the low number of patients in our study. The MICs show no intrinsic antifungal resistance. Azole therapy appears to be the first option, but nothing decides the choice between posaconazole or voriconazole except for the pharmacokinetics of each drug and its interactions with other medications. Decrease of immunosuppressive therapy might also contribute to improvement, and surgery can be a major part of treatment for some abscesses. However, as for many invasive fungal diseases, the final prognosis depends on that of the underlying disease.
Figure 3. Geographic distribution of 13 patients infected by Nannizziopsis obscura in West Africa. The different colors represent the number of cases in each country: red for 7 cases, orange for 2 cases,...
The main epidemiologic observation is the geographic origin of the patients. All came from sub-Saharan West Africa or Africa when national origin was reported (Tables 1, 2; Figure 3). The preferred migration routes explained by historical reasons—The Gambia to England route (7) and Mali, Senegal, and Guinea to France route—observed in our case-series and in the literature (6), might have introduced bias. However, France and England also have immigrants from other parts of Africa, and Nannizziopsis spp. infections are described only in patients from semiarid countries. For the previously reported patients from Nigeria (4,5), the exact origin was not reported, but Nigeria also covers semiarid tropical zones. In patients for whom the information was known, the delay between the last trip to Africa and the onset of symptoms varied between 2 months and 3 years (Table 1). Patients could carry latent forms of the fungus and have onset of an opportunistic infection when their immunity fails, as described for other fungi, such as Cryptococcus neoformans (17) and Histoplasma spp. or other endemic mycoses (18).
These 9 new cases and the previously reported cases (1,3–7) highlight the difficulties in identifying the N. obscura species complex. These fungal infections are likely underdiagnosed because of features shared with more common species, such as Trichophyton spp. or Trichosporon spp. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry should accelerate the process of identifying organisms and updating public databases, such as the online mass spectrometry platform (), which now includes a N. obscura profile. Up to now, these deep infections seemed to involve T-cell immunosuppressed patients with frequent dissemination or multifocus localizations. These molds are probably endemic in sub-Saharan Africa, but their precise geographic repartition and natural ecology remain to be established. Environmental studies would be necessary to further investigate the natural ecology of these molds, as has been done recently for the emerging Emergomyces africanus (19).
Dr. Garcia-Hermoso is a research engineer at the Centre National de Référence Mycoses Invasives et Antifongiques. Her main research focuses on the polyphasic identification of filamentous fungi causing invasive mycosis in humans and the phylogenetic relationship among different groups of fungal species.
Acknowledgments
The authors thank all the clinicians who cared for the patients, especially Aude Barnier in the case of patient 6. We thank Mohammad Akhoundi for his ITS2 sequencing; Cécile Gautier for technical assistance regarding culture of strains, MIC determinations, and PCR tests; and Eurofins Genomics France for strain sequencing. We are also deeply thankful to Françoise Dromer, who commented on the manuscript.
The National Reference Center for Invasive Mycoses and Antifungals is supported by the French Center for Diseases Control (Santé Publique France) and Institut Pasteur in Paris. The funders had no role in the study design, data collection, or analysis or interpretation of data.
References
- Stchigel AM, Sutton DA, Cano-Lira JF, Cabañes FJ, Abarca L, Tintelnot K, et al. Phylogeny of chrysosporia infecting reptiles: proposal of the new family Nannizziopsiaceae and five new species. Persoonia. 2013;31:86–100.
- Cabañes FJ, Sutton DA, Guarro J. Chrysosporium-related fungi and reptiles: a fatal attraction. PLoS Pathog. 2014;10:
e1004367 . - Stillwell WT, Rubin BD, Axelrod JL. Chrysosporium, a new causative agent in osteomyelitis. A case report. Clin Orthop Relat Res. 1984; (
184 ):190–2. - Steininger C, van Lunzen J, Sobottka I, Rohde H, Horstkotte MA, Stellbrink H-J. Mycotic brain abscess caused by opportunistic reptile pathogen. Emerg Infect Dis. 2005;11:349–50.
- Sigler L, Hambleton S, Paré JA. Molecular characterization of reptile pathogens currently known as members of the chrysosporium anamorph of Nannizziopsis vriesii complex and relationship with some human-associated isolates. J Clin Microbiol. 2013;51:3338–57.
- Nourrisson C, Vidal-Roux M, Cayot S, Jacomet C, Bothorel C, Ledoux-Pilon A, et al. Invasive infections caused by Nannizziopsis spp. molds in immunocompromised patients. Emerg Infect Dis. 2018;24:549–52.
- Baggott A, McGann H, Barton R, Ratner J. Disseminated Nannizziopsis obscura infection in a renal transplant patient- The first reported case. Med Mycol Case Rep. 2017;17:20–4.
- Fisher MC, Henk DA, Briggs CJ, Brownstein JS, Madoff LC, McCraw SL, et al. Emerging fungal threats to animal, plant and ecosystem health. Nature. 2012;484:186–94.
- Lanternier F, Cypowyj S, Picard C, Bustamante J, Lortholary O, Casanova J-L, et al. Primary immunodeficiencies underlying fungal infections. Curr Opin Pediatr. 2013;25:736–47.
- Guégan S, Garcia-Hermoso D, Sitbon K, Ahmed S, Moguelet P, Dromer F, et al.; French Mycosis Study Group. Ten-year experience of cutaneous and/or subcutaneous infections due to coelomycetes in France. Open Forum Infect Dis. 2016;3:
ofw106 . - Garcia-Hermoso D, Hoinard D, Gantier J-C, Grenouillet F, Dromer F, Dannaoui E. Molecular and phenotypic evaluation of Lichtheimia corymbifera (formerly Absidia corymbifera) complex isolates associated with human mucormycosis: rehabilitation of L. ramosa. J Clin Microbiol. 2009;47:3862–70.
- Kumar S, Stecher G, Tamura K. MEGA7: Molecular Evolutionary Genetics Analysis version 7.0 for bigger datasets. Mol Biol Evol. 2016;33:1870–4.
- Guindon S, Dufayard J-F, Lefort V, Anisimova M, Hordijk W, Gascuel O. New algorithms and methods to estimate maximum-likelihood phylogenies: assessing the performance of PhyML 3.0. Syst Biol. 2010;59:307–21.
- Lemoine F, Correia D, Lefort V, Doppelt-Azeroual O, Mareuil F, Cohen-Boulakia S, et al. NGPhylogeny.fr: new generation phylogenetic services for non-specialists. Nucleic Acids Res. 2019;47(W1):W260–5.
- Rouzaud C, Chosidow O, Brocard A, Fraitag S, Scemla A, Anglicheau D, et al.; French Mycoses Study Group. Severe dermatophytosis in solid organ transplant recipients: A French retrospective series and literature review. Transpl Infect Dis. 2018;20:
e12799 . - Brandt ME, Gaunt D, Iqbal N, McClinton S, Hambleton S, Sigler L. False-positive Histoplasma capsulatum Gen-Probe chemiluminescent test result caused by a Chrysosporium species. J Clin Microbiol. 2005;43:1456–8.
- Garcia-Hermoso D, Janbon G, Dromer F. Epidemiological evidence for dormant Cryptococcus neoformans infection. J Clin Microbiol. 1999;37:3204–9.
- Brunet K, Alanio A, Lortholary O, Rammaert B. Reactivation of dormant/latent fungal infection. J Infect. 2018;77:463–8.
- Schwartz IS, Lerm B, Hoving JC, Kenyon C, Horsnell WG, Basson WJ, et al. Emergomyces africanus in Soil, South Africa. Emerg Infect Dis. 2018;24:377–80.
Figures
Tables
Follow Up
Earning CME Credit
To obtain credit, you should first read the journal article. After reading the article, you should be able to answer the following, related, multiple-choice questions. To complete the questions (with a minimum 75% passing score) and earn continuing medical education (CME) credit, please go to . Credit cannot be obtained for tests completed on paper, although you may use the worksheet below to keep a record of your answers.
You must be a registered user on . If you are not registered on , please click on the “Register” link on the right hand side of the website.
Only one answer is correct for each question. Once you successfully answer all post-test questions, you will be able to view and/or print your certificate. For questions regarding this activity, contact the accredited provider, . For technical assistance, contact . American Medical Association’s Physician’s Recognition Award (AMA PRA) credits are accepted in the US as evidence of participation in CME activities. For further information on this award, please go to . The AMA has determined that physicians not licensed in the US who participate in this CME activity are eligible for AMA PRA Category 1 Credits™. Through agreements that the AMA has made with agencies in some countries, AMA PRA credit may be acceptable as evidence of participation in CME activities. If you are not licensed in the US, please complete the questions online, print the AMA PRA CME credit certificate, and present it to your national medical association for review.
Article Title:
Invasive Infections with Nannizziopsis obscura Species Complex in 9 Patients from West Africa, France, 2004–2020
Invasive Infections with Nannizziopsis obscura Species Complex in 9 Patients from West Africa, France, 2004–2020
CME Questions
1. Your patient is a 58-year-old immunocompromised man from sub-Saharan West Africa who presents with nodular skin lesions and a mass on chest radiology. On the basis of the case series of 9 patients by Garcia-Hermoso and colleagues, which one of the following statements about clinical features of invasive fungal infection with Nannizziopsis obscura species complex is correct?
A. Most patients had B-cell immunocompromise
B. The most frequently involved sites clinically were kidney and liver
C. Most patients who were treated received mainly azole therapy
D. There were no known deaths
2. According to the case series by Garcia-Hermoso and colleagues, which one of the following statements about microbiological features of invasive fungal infection with N. obscura species complex is correct?
A. Few isolates had low minimum inhibitory concentrations for the 8 antifungal drugs tested
B. The human strains of N. obscura were the same as those isolated from reptiles, based on multilocus sequence analysis
C. Nannizziopsis spp. have specific features in culture
D. The most common finding at pathology or direct microbiological examination was the presence of nonspecific hyaline, septate, smooth-walled hyphae
3. On the basis of the case series by Garcia-Hermoso and colleagues, which one of the following statements about clinical implications of features of invasive fungal infection with N. obscura species complex is correct?
A. N. obscura infection is probably underestimated, as identification is possible only by sequencing, which requires a tissue biopsy
B. The study proves that the portal of entry is via breaks in the skin
C. The study proves that voriconazole is the initial treatment of choice
D. Pharmacotherapy is the only treatment option
Original Publication Date: August 14, 2020
1Preliminary results of this study were presented at the International Society for Human and Animal Mycology, June 30–July 4, 2018, Amsterdam, the Netherlands (poster 174, Medical Mycology 56, Supplement 2).
No hay comentarios:
Publicar un comentario